The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to provide leadership across the NTCN to design and efficiently perform clinical trials evaluating the safety and efficacy of novel regimens or modifications of existing regimens;(b) to provide leadership in biomarker development and in integration of new technologies into NCTN trials, taking advantage of a systematic approach to collection, processing, and storage of blood, normal tissue, fresh or frozen tumor tissue, and other relevant biologic samples for molecular and pharmacologic studies;and (c) to evaluate cancer treatment regimens in special patient populations, such as rare cancers, the elderly and ethnic minorities. USC investigators have not only contributed extensively to SWOG trials but have demonstrated administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Recent SWOG trials evaluating the predictive role of ERCC1 expression in the outcome of patients with metastatic gastric cancer and the role of CTC enumeration and telomerase activity in prostate cancer highlight one aspect of the scientific leadership that USC investigators have provided in the NCI cooperative group system. They have also played an active role in NCI task forces and steering committees. As part of its dedication to cancer clinical research, USC has been successful in mentoring young investigators through the SWOG Young Investigator Awards (10) and has expanded its institutional training capabilities. Lastly, as a Network Lead Academic Participating Site, USC will continue to bring unique strengths to the NCI National Clinical Trials Network thanks to its strength in recruitment of minorities to clinical trials, accrual to rare cancers such as biliary and bladder cancers, and a well-developed clinical research infrastructure.

Public Health Relevance

The USC UI0 will provide leadership, accelerate preclinical findings generated at USC into clinical trials in the NCTN, improve outcomes for patients with solid and liquid tumors, and improve quality of life. We will identify and validate molecular signatures, tailoring chemotherapy, to increase efficacy and decrease toxicity, and identify novel targets for drug development using specimens collected in NCTN clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180830-01
Application #
8605629
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2014-04-17
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Suenaga, M; Schirripa, M; Cao, S et al. (2017) Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol 28:1015-1022
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Venook, Alan P; Niedzwiecki, Donna; Lenz, Heinz-Josef et al. (2017) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317:2392-2401
Berger, M D; Stintzing, S; Heinemann, V et al. (2017) Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol 28:2780-2785
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Fujii, Takeo; Barzi, Afsaneh; Sartore-Bianchi, Andrea et al. (2017) Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 23:3657-3666
Ricker, Charité N; Hanna, Diana L; Peng, Cheng et al. (2017) DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer 123:3732-3743
van Geel, Robin M J M; Tabernero, Josep; Elez, Elena et al. (2017) A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov 7:610-619
Salem, Mohamed E; Weinberg, Benjamin A; Xiu, Joanne et al. (2017) Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 8:86356-86368
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641

Showing the most recent 10 out of 27 publications